Valneva has moved a step closer to its goal of becoming the first company to file for approval of a vaccine against chikungunya virus in the US after reporting new clinical data today.
According to the World Health Organization (WHO), approximately 296 million people globally live with hepatitis B, with most unaware of their infection.
